Dianthus Therapeutics, Inc. (NASDAQ:DNTH) Receives Consensus Rating of “Moderate Buy” from Brokerages

Dianthus Therapeutics, Inc. (NASDAQ:DNTH) has been assigned an average rating of “Moderate Buy” from the ten brokerages that are covering the firm, MarketBeat reports. One equities research analyst has rated the stock with a sell rating and nine have issued a buy rating on the company. The average 12 month price objective among brokerages that have covered the stock in the last year is $67.6250.

A number of research firms have issued reports on DNTH. Jefferies Financial Group raised their target price on Dianthus Therapeutics from $66.00 to $81.00 and gave the company a “buy” rating in a report on Monday, February 2nd. Wedbush upped their target price on shares of Dianthus Therapeutics from $46.00 to $55.00 and gave the stock an “outperform” rating in a report on Wednesday, February 11th. Weiss Ratings reissued a “sell (d-)” rating on shares of Dianthus Therapeutics in a research note on Wednesday, January 21st. HC Wainwright upped their price objective on Dianthus Therapeutics from $40.00 to $47.00 and gave the stock a “buy” rating in a report on Monday, November 10th. Finally, Truist Financial raised their target price on shares of Dianthus Therapeutics from $56.00 to $63.00 and gave the company a “buy” rating in a research note on Thursday, January 8th.

Insiders Place Their Bets

In related news, CFO Ryan Savitz sold 20,000 shares of the business’s stock in a transaction that occurred on Thursday, December 4th. The shares were sold at an average price of $45.18, for a total transaction of $903,600.00. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through this link. 16.56% of the stock is owned by insiders.

Hedge Funds Weigh In On Dianthus Therapeutics

Institutional investors have recently modified their holdings of the business. Patient Square Capital LP bought a new position in Dianthus Therapeutics during the 3rd quarter worth about $4,919,000. XTX Topco Ltd bought a new stake in Dianthus Therapeutics during the second quarter worth $503,000. Sio Capital Management LLC grew its holdings in Dianthus Therapeutics by 101.8% during the second quarter. Sio Capital Management LLC now owns 236,070 shares of the company’s stock worth $4,398,000 after purchasing an additional 119,073 shares during the period. Ensign Peak Advisors Inc bought a new position in Dianthus Therapeutics during the second quarter worth $2,504,000. Finally, Candriam S.C.A. increased its position in Dianthus Therapeutics by 25.3% during the 3rd quarter. Candriam S.C.A. now owns 301,428 shares of the company’s stock worth $11,861,000 after buying an additional 60,852 shares during the period. Institutional investors own 47.53% of the company’s stock.

Dianthus Therapeutics Stock Performance

DNTH opened at $52.86 on Wednesday. The stock has a 50-day moving average of $46.03 and a 200-day moving average of $38.72. Dianthus Therapeutics has a 52-week low of $13.36 and a 52-week high of $57.50. The company has a market cap of $2.28 billion, a PE ratio of -15.19 and a beta of 1.59.

Dianthus Therapeutics Company Profile

Dianthus Therapeutics, Inc, a clinical-stage biotechnology company, develops complement therapeutics for patients with severe autoimmune and inflammatory diseases. It is developing DNTH103, a monoclonal antibody, which is in Phase 2 clinical trial, for the treatment of generalized myasthenia gravis, multifocal motor neuropathy, and chronic inflammatory demyelinating polyneuropathy. Dianthus Therapeutics, Inc was founded in 2019 and is headquartered in New York, New York.